Rubella virus vaccine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Rubella virus vaccine is a vaccine used to prevent Rubella.

Brand Names
M-M-R II, Proquad
Generic Name
Rubella virus vaccine
DrugBank Accession Number
DB10317
Background

Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Attenuated
Synonyms
  • Rubella virus (vaccine strain ra27/3) live antigen
  • Rubella virus live antigen, A
  • Rubella virus strain wistar ra 27/3 live (attenuated) antigen
  • Rubella virus strain wistar ra 27/3 live antigen
  • Rubella virus vaccine live (wistar ra 27-3 strain)
  • Rubella virus vaccine,live
  • Rubella, live attenuated
  • Rubivirus rubella virus wistar ra 27/3 whole

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Abatacept.
AcyclovirThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Acyclovir.
AdalimumabThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Adalimumab.
Adefovir dipivoxilThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Adefovir dipivoxil.
AldesleukinThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Aldesleukin.
AlefaceptThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Alefacept.
AlemtuzumabThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Alemtuzumab.
AltretamineThe risk or severity of infection can be increased when Rubella virus vaccine is combined with Altretamine.
AmantadineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Amantadine.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
International/Other Brands
Meruvax II
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
M-M-R IIRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousMerck Sharp & Dohme Corp.1971-04-21Not applicableUS flag
M-M-R IIRubella virus vaccine (1000 TCID50/0.5mL) + Measles virus vaccine live attenuated (1000 TCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50/0.5mL)Powder, for solutionSubcutaneousMerck Ltd.1979-12-31Not applicableCanada flag
M-M-R IIRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousA-S Medication Solutions1971-04-21Not applicableUS flag
M-M-R IIRubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousPhysicians Total Care, Inc.1996-08-072012-06-30US flag
M-M-rvaxproRubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50)Msd Vaccins2021-02-10Not applicableEU flag
M-M-rvaxproRubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50)Msd Vaccins2021-02-10Not applicableEU flag
M-M-rvaxproRubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50)Msd Vaccins2021-02-10Not applicableEU flag
M-M-rvaxproRubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50)Injection, powder, for suspensionIntramuscular; SubcutaneousMsd Vaccins2021-02-10Not applicableEU flag
M-M-rvaxproRubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50)Msd Vaccins2021-02-10Not applicableEU flag
M-M-rvaxproRubella virus vaccine (1000 TCID50) + Measles virus vaccine live attenuated (1000 TCID50) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50)Msd Vaccins2021-02-10Not applicableEU flag

Categories

ATC Codes
J07BD53 — Measles, combinations with rubella, live attenuatedJ07BD54 — Measles, combinations with mumps, rubella and varicella, live attenuatedJ07BD52 — Measles, combinations with mumps and rubella, live attenuatedJ07BJ01 — Rubella, live attenuatedJ07BJ51 — Rubella, combinations with mumps, live attenuatedJ07BD51 — Measles, combinations with mumps, live attenuated
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
52202H034Z
CAS number
Not Available

References

General References
  1. TITCK Product Information: R-VAC (rubella vaccine, live, attenuated) for subcutaneous injection [Link]
PubChem Substance
347910496
RxNav
9486

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingPreventionChildren / Death / Measles Vaccination / Morbidity / Non-specific/Heterologous Effects of Vaccines / Oral Polio Vaccine1
4Active Not RecruitingPreventionDeath / Hospital Admission / Measles Vaccine / Non-specific (Heterologous) Effects of Vaccines1
4Active Not RecruitingPreventionHepatitis A / Rubeola / Varicella1
4CompletedNot AvailableRheumatoid Arthritis, Juvenile1
4CompletedDiagnosticDiphtheria / Pertussis / Rubeola / Tetanus1
4CompletedPreventionAdverse Event Following Immunization / Mumps / Rubella / Rubeola1
4CompletedPreventionBCG Infection / Immune Responses / Vaccine Reaction1
4CompletedPreventionChickenpox / Hepatitis A / Mumps / Rubella / Rubeola1
4CompletedPreventionDeath / Vaccines1
4CompletedPreventionEncephalitis, Japanese B1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, lyophilized, for solutionSubcutaneous
Injection, powder, lyophilized, for suspensionSubcutaneous
Injection, powder, for suspensionIntramuscular; Subcutaneous
Injection, powder, lyophilized, for solutionIntramuscular; Subcutaneous
Injection, powder, for solutionSubcutaneous
Kit; powder, for solutionIntramuscular; Subcutaneous
Injection, solutionIntramuscular; Subcutaneous
Injection, powder, for solutionIntramuscular; Subcutaneous
Injection
Injection, powder, lyophilized, for suspensionIntramuscular; Subcutaneous
Powder, for solutionSubcutaneous
InjectionSubcutaneous
InjectionSubcutaneous
Injection, powder, lyophilized, for suspensionSubcutaneous
Solution
Injection, powder, lyophilized, for suspension
Powder
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 20:03 / Updated on February 13, 2021 10:52